Friday, August 3, 2018

4 High-Growth Solar Stocks Investors Should Watch

Many perceive solar energy as a panacea for deriving power from so-called “clean energy” sources. Although solar does not consume fossil fuels or create emissions, higher production costs made it less viable, and by extension, solar stocks less worthy of investment in past decades.

However, improvements in both battery storage and solar technology have made this form of energy more economical. Over the last few years, several companies have emerged to bring solar energy to the market. Many have devoted large swaths of land to solar panels. Others have again begun to place panels on the roofs of residential homes.

Like all stocks in an investment sector, some remain better buys than others. These four equities provide a compelling opportunity for long-term profits in this high-growth sector:


Compare Brokers
Solar Stocks to Buy: Solaredge Technologies (SEDG) Solar Stocks to Buy: Solaredge Technologies (SEDG)Source: Shutterstock

Solaredge Technologies (NASDAQ:SEDG) stands out among solar stocks. The company sells power optimizers, inverters and monitoring platforms in the solar space. This allows SEDG to specialize in residential, while also serving the commercial and small-utility markets. They sell directly to installers, wholesalers and other firms involved in construction.

SEDG stock offers two distinct advantages. First, it poses fewer geopolitical risks than most other stocks. With its base of operations in Israel, it will likely not face the tariffs that counterparts in China and other countries in the crosshairs of the Trump Administration face.

Second, SEDG stock is hard to beat among solar stocks. Revenue rose by an average of 46.1%-per-year over the last five years. The company also turned profitable in 2015 and continues to grow these profits at double-digit rates. Analysts predict that rate of growth will continue at least through the next year.

The recent performance of the stock also bodes well. The stock initially struggled following its IPO in the spring of 2015. However, SEDG stock established a bottom of $11.35-per-share in 2016. Since then, the stock has seen a steady move higher. Today, it trades in the $56-per-share range. Despite this five-fold surge, SEDG stock supports a forward price-to-earnings (P/E) ratio of about 17.1. This should leave plenty of room for growth in the months and years to come.


Compare Brokers
Solar Stocks to Buy: Sunrun Inc (RUN) Solar Stocks to Buy: Sunrun Inc (RUN)Source: Shutterstock

Sunrun (NASDAQ:RUN) specializes in home solar panels and storage equipment. The San Francisco-based company claims itself as the largest solar company in the United States that dedicates itself to residential.

RUN works to bring solar directly to homes with little upfront cost and at a lower overall cost than traditional providers of electricity. They design, install and maintain the panels on the homeowner’s roof and offer what they describe as “predictable pricing” for a minimum of 20 years. With this arrangement, Sunrun provides a compelling value proposition among solar stocks. Also, since the company operates only in the U.S., it has little exposure to the trade issues that plague other solar companies.

Despite years of struggles, SUN stock appears to have gained Wall Street’s attention. After an IPO in August 2015, the stock quickly fell into the single digits. It spent most of the time since mired in a trading range. However, since February, the stock has risen from a low of just above $5-per-share in February to almost $14.50-per-share today.

Despite the run (pun intended), RUN stock trades at a reasonable valuation. Forecasts for profits in 2018 vary widely. However, even the lowest projections place the forward P/E at a level of 16.6. The company also saw about 40% average revenue growth per year over the last three years. Even if revenue growth slows down in future years, profits should continue to increase significantly.


Compare Brokers
Solar Stocks to Buy: Vivint Solar (VSLR)

Solar Stocks to Buy: Vivint Solar (VSLR)

Vivint Solar (NASDAQ:VSLR) tops the list as one of the more consumer-focused solar plays. Based in Lehi, Utah, it generates its solar power through a proprietary process. It places residences under long-term contracts and installs solar systems at people’s respective homes. They operate in 21 states, mostly in the southwestern part of the country and along the east coast.

Among solar stocks, VSLR has stood out for its growth. The company doubled revenue in previous years. Although that growth has slowed, revenue growth should remain at double-digit levels for the foreseeable future. It also continually supports low multiples. As a small, fast-growing company, it does not earn a profit. However, its price-to-sales (P/S) ratio stands at just above 2.3. Also, it also trades at just over 2.1 times its book value.

The company remains in a start-up mode with a market cap just under $650 million. Profitability also remains years off. However, after sinking below $2.50 following an IPO at $16-per-share in 2014, the stock has slowly recovered. It currently trades above $5.50-per-share. If it can keep growing, VSLR stock should rise with it. Investors need to keep the speculative nature of the company in mind. However, if one feels comfortable with the risks, VSLR stock could become rewarding in the years to come.


Compare Brokers
Solar Stocks to Buy: JinkoSolar (JKS) Solar Stocks to Buy: JinkoSolar (JKS)Source: Shutterstock

Admittedly, JinkoSolar (NYSE:JKS) stands as one of the riskier solar stocks. Even though it incorporated in the Cayman Islands, their actual base of operations resides in Shanghai. As such, it finds itself in the middle of the U.S.-China trade war. Consequently, the JKS stock price has fallen as a result.

But here’s the thing.

Even though the United States will remain an important market for decades to come, 95% of the world’s population resides outside of the U.S. Moreover, most economists believe that the economic center of gravity continues to shift across the Pacific to Asia. For these reasons, I think investors should consider JKS stock at a discount no matter how any trade dispute plays out.

Such a discount has likely materialized. Since last September, JKS stock has fallen from a high of $30.90-per-share all the way to the $14-per-share range. Profit forecasts vary widely due to this trade war. However, we know that revenue grew by an average of 40.7%-per-year over the last five years. Moreover, despite variations, all predictions would take the forward P/E of JKS stock no higher than 10. The current decline has brought the stock’s current P/E to about 10.8.

Anything can happen in the current trade war. Those with a low appetite for risk should probably look to other stocks. However, for those who believe that this dispute will remain a short-term phenomenon, JKS holds the potential to become one of the higher-performing solar stocks.

As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow him on Twitter

Sunday, July 22, 2018

AJ Wealth Strategies LLC Has $6.93 Million Holdings in Corcept Therapeutics Incorporated (CORT)

AJ Wealth Strategies LLC raised its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 113.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 441,103 shares of the biotechnology company’s stock after acquiring an additional 234,483 shares during the quarter. Corcept Therapeutics comprises approximately 1.4% of AJ Wealth Strategies LLC’s portfolio, making the stock its 14th biggest holding. AJ Wealth Strategies LLC owned approximately 0.38% of Corcept Therapeutics worth $6,934,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of CORT. BlackRock Inc. grew its position in shares of Corcept Therapeutics by 13.2% during the 1st quarter. BlackRock Inc. now owns 12,905,164 shares of the biotechnology company’s stock valued at $212,288,000 after purchasing an additional 1,505,877 shares in the last quarter. Federated Investors Inc. PA grew its position in shares of Corcept Therapeutics by 0.5% during the 1st quarter. Federated Investors Inc. PA now owns 12,686,727 shares of the biotechnology company’s stock valued at $208,697,000 after purchasing an additional 62,715 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Corcept Therapeutics by 24.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,576,649 shares of the biotechnology company’s stock valued at $25,936,000 after purchasing an additional 306,691 shares in the last quarter. Northern Trust Corp grew its position in shares of Corcept Therapeutics by 0.5% during the 1st quarter. Northern Trust Corp now owns 1,116,603 shares of the biotechnology company’s stock valued at $18,368,000 after purchasing an additional 5,342 shares in the last quarter. Finally, Nexthera Capital LP purchased a new position in shares of Corcept Therapeutics during the 1st quarter valued at $17,193,000. 76.43% of the stock is currently owned by institutional investors and hedge funds.

Get Corcept Therapeutics alerts:

Corcept Therapeutics traded down $0.39, hitting $13.22, during midday trading on Thursday, Marketbeat Ratings reports. The company had a trading volume of 2,865,100 shares, compared to its average volume of 1,574,573. Corcept Therapeutics Incorporated has a 52-week low of $11.88 and a 52-week high of $25.96. The firm has a market capitalization of $1.60 billion, a PE ratio of 30.07 and a beta of 1.93.

Corcept Therapeutics (NASDAQ:CORT) last announced its earnings results on Tuesday, May 8th. The biotechnology company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.01. Corcept Therapeutics had a net margin of 75.05% and a return on equity of 46.78%. The company had revenue of $57.66 million during the quarter, compared to analyst estimates of $58.18 million. During the same period in the previous year, the business earned $0.06 earnings per share. The firm’s quarterly revenue was up 108.9% compared to the same quarter last year. equities analysts predict that Corcept Therapeutics Incorporated will post 0.73 earnings per share for the current fiscal year.

In related news, Director G Leonard Baker, Jr. sold 30,000 shares of the company’s stock in a transaction on Friday, May 11th. The shares were sold at an average price of $16.01, for a total value of $480,300.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Robert S. Fishman sold 8,000 shares of the company’s stock in a transaction on Friday, July 6th. The stock was sold at an average price of $15.09, for a total transaction of $120,720.00. Following the completion of the transaction, the insider now owns 8,000 shares of the company’s stock, valued at $120,720. The disclosure for this sale can be found here. Insiders sold 54,000 shares of company stock valued at $888,300 over the last quarter. 15.00% of the stock is owned by company insiders.

A number of research analysts have recently commented on CORT shares. Stifel Nicolaus lowered shares of Corcept Therapeutics from a “buy” rating to a “hold” rating and set a $20.00 price target for the company. in a research report on Thursday, May 31st. Seaport Global Securities assumed coverage on shares of Corcept Therapeutics in a research report on Friday, April 13th. They set a “buy” rating and a $32.00 price target for the company. Zacks Investment Research upgraded shares of Corcept Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 target price for the company in a research report on Friday, April 27th. BidaskClub upgraded shares of Corcept Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, April 20th. Finally, ValuEngine upgraded shares of Corcept Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, May 14th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $26.20.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression.

Read More: Closed-End Mutual Funds

Want to see what other hedge funds are holding CORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corcept Therapeutics Incorporated (NASDAQ:CORT).

Institutional Ownership by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Friday, July 20, 2018

Stocks in the news: UltraTech Cement, HDFC, IDBI Bank, Kridhan Infra, PNC Infratech

Here are the stocks that are in news today:

Results Today:�UltraTech Cement, Bandhan Bank, Mindtree, NIIT Technologies, JM Financial, Mastek, GHCL, Mahindra CIE Auto, Reliance Communications, Sasken Tech, Responsive Industries, JK Tyre & Industries, Foseco India, HT media, Artson Engineering

HDFC: HDFC Asset Management Company decided to open its initial public offering for subscription on July 25 and close on July 27. Price band is fixed at Rs 1,095 to Rs 1,100 per share.

IDBI Bank: The bank has received a letter from Life Insurance Corporation of India expressing their interest in acquiring 51 percent controlling stake in the bank, as a Promoter through preferential allotment of shares/open offer.

related news Stocks in the news: Ashok Leyland, HCL Info, HUL, JSW Energy, Glenmark Pharma, BEML Stocks in the news: Tata Motors, Infosys, HUL, Vedanta, Aurobindo Pharma, JSPL, Just Dial Stocks in the news: Infosys, Fortis, Vakrangee, Cyient, HCL Tech, HOEC, Novartis, HDFC Bank

PSU Banks: The government has announced a capital infusion of Rs 11,336 crore in five public sector banks, which include�Punjab National Bank�(Rs 2,816 crore),�Indian Overseas Bank�(Rs 2,157 crore),�Andhra Bank�(Rs 2,019 crore),�Corporation Bank�(Rs 2,555 crore) and�Allahabad Bank�(Rs 1,790 crore).

Zee Entertainment Enterprises: Q1 consolidated net profit up 31.2 percent at Rs 326 crore versus Rs 248.2 crore; revenue up 15 percent at Rs 1,772 crore versus Rs 1,504.3 crore (YoY).

Sintex Industries: Q1 consolidated profit up 11.5 percent at Rs 39.1 crore versus Rs 35.1 crore; revenue up 34.6 percent at Rs 925.3 crore versus Rs 687.6 crore (YoY).

5paisa Capital: Q1 consolidated loss at Rs 5.6 crore versus loss of Rs 6.2 crore; revenue rises to Rs 9 crore versus Rs 2.2 crore (YoY).

HDFC Bank: The bank will issue 3.91 crore shares to HDFC via preferential allotment at Rs 2,174.09 per share.

Tejas Networks: Tejas implements 100G DWDM network for MCM Telecom in Mexico.

Kridhan Infra: VNC's JV awarded order worth Rs 222.6 crore.

PNC Infratech: The concession agreement signed between National Highways Authority of India and PNC Challakere (Karnataka) Highways Private Limited [special purpose vehicle] incorporated for implementation of project of four laning of Challakere to Hariyur section of NH 150 A, in Karnataka on Hybrid Annuity Mode.

Vibrant Global Capital: Board approved further Investment in Vibrant Global Salt Private Limited (subsidiary company) by way of purchase of 7 lakh Equity Shares in VGSPL. By way of this proposed investment, VGSPL will become wholly-owned subsidiary of the company.

REC board to consider raising up to Rs 70K cr via NCDs

Jet Airways to hold 26th AGM on August 9

NCLAT stays voting by Bhushan Power & Steel lenders on finalising bids

Allahabad Bank plans Rs 1,900 cr equity capital mop-up

Kalpataru Power Transmission to seek shareholders' nod to raise up to Rs 300 cr

Well mgt Co LLP sold 37,45,651 shares of PC Jeweller at Rs 85.43 First Published on Jul 18, 2018 07:44 am

Friday, July 13, 2018

Intellect Design Q1 PAT may dip 22.8% QoQ to Rs. 20 cr: HDFC Securities


HDFC Securities has come out with its first quarter (April-June�� 18) earnings estimates for the Technology sector. The brokerage house expects Intellect Design to report net profit at Rs. 20 crore down 22.8% quarter-on-quarter.


Net Sales are expected to increase by 3.5 percent Q-o-Q (up 31.8 percent Y-o-Y) to Rs. 318 crore, according to HDFC Securities.


Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 6.7 percent Q-o-Q (up 62.6 percent Y-o-Y) to Rs. 26 crore.


Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More First Published on Jul 12, 2018 05:50 pm

Thursday, July 12, 2018

The United States could be spared the worst in a trade war

Mohamed El-Erian thinks a trade war will hurt the global economy. But it'll hurt the United States less than others.

In a piece for Project Syndicate, Allianz's chief economic adviser wrote that "today, a trade war would damage all economies."

But, he added, the United States "would do better than most others in a contracting world economy. Already, Chinese financial markets have suffered, while those in the US have held their own."

The investing expert will join CNNMoney editor-at-large Richard Quest on "Markets Now" on Wednesday.

In addition to the ramifications of a trade war, El-Erian and Quest will discuss the importance of continuing job growth to the US economy, the best sectors to invest in today and when bitcoin can be a good bet.

Recently, El-Erian said on CNBC's "Squawk Box" that he'd buy bitcoin if it fell to about $5,000 per coin.

The price of one bitcoin is now hovering around $6,400. That's a more than 50% drop in 2018 and a 66% plunge from the all-time high of just under $20,000 that bitcoin hit in late December.

CNNMoney's "Markets Now" streams live from the New York Stock Exchange every Wednesday at 12:45 p.m. ET. Hosted by Quest, the 15-minute program features incisive commentary from experts.

Recent guests include BlackRock's (BLK)Rick Rieder, Stifel Chief Economist Lindsey Piegza and bitcoin bull Mike Novogratz.

You can watch "Markets Now" at CNNMoney.com/MarketsNow from your desk or on your phone or tablet. If you can't catch the show live, check out highlights online and through the Markets Now newsletter, delivered to your inbox every afternoon.

Tuesday, July 10, 2018

Fidelity National Financial (FNF) to Release Earnings on Tuesday

Fidelity National Financial (NYSE:FNF) will post its quarterly earnings results after the market closes on Tuesday, July 17th. Analysts expect Fidelity National Financial to post earnings of $0.82 per share for the quarter.

Fidelity National Financial (NYSE:FNF) last announced its earnings results on Wednesday, May 2nd. The financial services provider reported $0.42 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.42. Fidelity National Financial had a return on equity of 13.04% and a net margin of 8.66%. The firm had revenue of $1.69 billion for the quarter, compared to the consensus estimate of $1.70 billion. During the same period in the previous year, the business earned $0.42 EPS. On average, analysts expect Fidelity National Financial to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Get Fidelity National Financial alerts:

Shares of Fidelity National Financial opened at $38.29 on Tuesday, Marketbeat Ratings reports. Fidelity National Financial has a 1-year low of $31.89 and a 1-year high of $42.52. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 0.17. The firm has a market cap of $10.40 billion, a P/E ratio of 16.87 and a beta of 0.80.

The firm also recently announced a quarterly dividend, which was paid on Friday, June 29th. Investors of record on Friday, June 15th were paid a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a yield of 3.13%. This is an increase from Fidelity National Financial’s previous quarterly dividend of $0.27. The ex-dividend date of this dividend was Thursday, June 14th. Fidelity National Financial’s payout ratio is 52.86%.

In other Fidelity National Financial news, insider Brent B. Bickett sold 63,155 shares of Fidelity National Financial stock in a transaction dated Tuesday, April 17th. The stock was sold at an average price of $39.10, for a total transaction of $2,469,360.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Anthony Park sold 55,779 shares of Fidelity National Financial stock in a transaction dated Thursday, June 21st. The stock was sold at an average price of $36.99, for a total value of $2,063,265.21. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 119,998 shares of company stock valued at $4,573,185. 6.10% of the stock is currently owned by insiders.

A number of brokerages have commented on FNF. Zacks Investment Research raised Fidelity National Financial from a “sell” rating to a “hold” rating in a research report on Friday. ValuEngine cut Fidelity National Financial from a “hold” rating to a “sell” rating in a research report on Tuesday, May 22nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $43.83.

Fidelity National Financial Company Profile

Fidelity National Financial, Inc, together with its subsidiaries, provides title insurance, technology, and transaction services to the real estate and mortgage industries in the United States. The company operates in Title, and Corporate and Other segments. It offers title insurance, escrow, and other title related services, including collection and trust activities, trustee sales guarantees, recordings and conveyances, and home warranty insurance.

Earnings History for Fidelity National Financial (NYSE:FNF)

Monday, July 9, 2018

K&S (SDF) Given a €25.00 Price Target by Deutsche Bank Analysts

Deutsche Bank set a €25.00 ($29.07) price objective on K&S (ETR:SDF) in a report published on Tuesday. The brokerage currently has a neutral rating on the stock.

Several other analysts have also commented on the company. UBS Group set a €25.00 ($29.07) price target on K&S and gave the company a buy rating in a research note on Tuesday, March 6th. Credit Suisse Group set a €19.30 ($22.44) price target on K&S and gave the company a sell rating in a research note on Monday, March 19th. Independent Research set a €25.00 ($29.07) price target on K&S and gave the company a neutral rating in a research note on Friday, March 16th. Warburg Research set a €24.60 ($28.60) price target on K&S and gave the company a neutral rating in a research note on Wednesday, March 28th. Finally, Commerzbank set a €25.00 ($29.07) price target on K&S and gave the company a buy rating in a research note on Thursday, March 8th. Five analysts have rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of Hold and an average price target of €23.74 ($27.60).

Get K&S alerts:

Shares of SDF stock opened at €20.71 ($24.08) on Tuesday. K&S has a one year low of €18.92 ($22.00) and a one year high of €24.74 ($28.77).

About K&S

K+S Aktiengesellschaft, together with its subsidiaries, produces and sells potash, magnesium, and salt products worldwide. Its Potash and Magnesium Products segment produces and markets mineral fertilizers, such as potassium chloride for various crops, including cereals, corn, rice, and soy beans; fertilizer specialties for rapeseeds, potatoes, citrus fruits, vines, and vegetables; potassium and magnesium products for industrial applications; and a range of products for use in pharmaceutical, cosmetics, food processing, and animal feed industries.

Analyst Recommendations for K&S (ETR:SDF)

Friday, July 6, 2018

2 Biotech Stocks at New Lows. Can They Recover?

It's been a rough year for these two biotechs and their unhappy shareholders. Denali Therapeutics Inc. (NASDAQ:DNLI)�stock isn't much older than last year's Christmas presents, but shares have already tumbled 39% from a peak set in February.�MiMedx Group, Inc. (NASDAQ:MDXG)�also peaked in February, but rumors of impropriety knocked the stock down 75% since then.

There have been years of steady stock gains across the board, and now, distressed companies are one of the few places left to shop for bargains. Let's see if any of these stocks have a path to recovery that might make them worth another look.

Business people looking down at a peer laying flat on his stomach on the ground.

Image source: Getty Images.

Denali Therapeutics Inc.: Down, but still high

This sparkly new biotech stock fell hard following its�initial public offering (IPO) last December, then recovered briefly after announcing a new partnership with�Takeda. The company hasn't run into any significant trouble recently, but the stock just approached another all-time low. Despite the slide, this start-up still has a $1.4 billion market cap that could fall a lot lower if its new drug candidates aren't as valuable as hoped.

Denali's developing a slate of experimental drugs aimed at targets in the brain that have been implicated in different neurodegenerative diseases that lack effective treatment options, such as Alzheimer's disease and Parkinson's disease. The company thinks its proprietary transport technology will help it get big drugs across the tricky blood-brain barrier -- but that's just a beginning.

The neurodegenerative diseases that Denali aims to treat, such as Alzheimer's, progress very slowly. Coupled with the fact that cognitive benefits are difficult to measure and compare from one person to the next, it's no wonder there's a dearth of drugs to stop the diseases this company wants to treat. Denali intends to use lots of patient data to select trial participants most likely to respond to its drug candidates, but there's no getting around the fact that you have to follow them around for years before you'd know if you have a new drug candidate with any potential.

Lab scientist looking up close at a medicine capsule.

Image source: Getty Images.

Denali stock could rise several times over if its drugs work for real people, but it's going to be a long time before we know if there's anything here worth getting excited about. Investigators have begun healthy volunteer studies, but the first human proof-of-concept trials aren't slated to begin until the end of the year, at best.

Denali's operations lost $90 million last year, and running new clinical trials will probably accelerate the losses going forward. The company finished March with a healthy $373 million in cash and short-term investments, which suggests it has another couple of years to show some results before it has to tap investors for more.

If the first trial results aren't terrific, though, investors could lose a bundle. Given the odds of success in this tough field, I'd steer clear of this stock until there's some data to evaluate.

MiMedx Group, Inc.: Restate and regenerate?

This company's stock has tumbled around 77% from a peak reached less than five months ago. That's what telling investors that your latest financial report is unreliable as you march your CEO out the door will do to a stock.

The Board of Directors concluded that it will need to restate five years of financials. If the restatements don't deviate too far from stated results, though, this stock could move up nicely.�

MDXG Revenue (TTM) Chart

MDXG Revenue (TTM) data by YCharts.

Over the past several years, MiMedx Group�reported�steady sales growth among its placenta-based tissue-regeneration products. The hammering of the stock this year, however, is in response to fears the company may have overcharged the government.�

What we do know is that top-line revenue wasn't growing much faster than sales, general, and administrative expenses to begin with. If operations have been relying on dubious practices to earn a modest profit, the company's troubles could go far beyond legal expenses.

On the other hand, MiMedx Group is in a strong financial position with positive cash flows and no significant debt to pay down. The shares have been trading at just 1.1 times this year's sales expectations, which is awfully cheap for a profitable business with steadily rising sales. If the company emerges from ongoing investigations relatively unscathed, intrepid investors will be greatly rewarded.

Just because it could rise doesn't mean you should buy

The odds of Denali scoring enough wins in neurology to justify its sky-high valuation are long, but I think there's a solid chance MiMedx will emerge from ongoing investigations with both feet on the ground. While that will make it a fun stock to watch, it probably isn't right for your portfolio.

Once MiMedx restates five years of earnings, your investment could get wiped out if it turns out the company really can't sell regenerative tissue at a profit. Until we can be certain this isn't the case, I wouldn't put any money here.

Thursday, July 5, 2018

How Sensitive Is Pfizer To R&D Expense Changes?

&l;p&g;We estimate that &l;a href=&q;http://finapps.forbes.com/finapps/jsp/finance/compinfo/CIAtAGlance.jsp?tkr=pfe&a;amp;tab=searchtabquotesdark&q; target=&q;_blank&q;&g;Pfizer&a;rsquo;s&l;/a&g; (NYSE:PFE) R&a;amp;D expenses will grow in low single digits to $7.8 billion in 2018. However, we expect a slight decline in R&a;amp;D expenditure as a percentage of Pfizer&a;rsquo;s gross profit. Of late, many large pharmaceutical firms are becoming more financially disciplined in order to protect their earnings, which are under threat due to patent expiries for key drugs. Over the last few years, Pfizer has lost its patent exclusivity for some of its drugs, and it will lose patent exclusivity for Lyrica this year. Lyrica&a;rsquo;s annual sales were over $5 billion in 2017. While Pfizer has a solid portfolio of new drugs, which will likely offset the revenue declines that are expected from the loss of patent exclusivity for drugs in the coming years, we expect the company to be prudent about its R&a;amp;D spending. We have created an interactive dashboard analysis ~ &l;a href=&q;http://dashboards.trefis.com/no-login-required/oDtgFxAH?fromforbesandarticle=how-sensitive-is-pfizer-to-rd-expense-changes&q; target=&q;_blank&q;&g;&l;strong&g;How Sensitive Is Pfizer To R&a;amp;D Expense Changes?&l;/strong&g;&l;/a&g; Note that you can adjust the R&a;amp;D drivers, and see the impact on Pfizer&a;rsquo;s overall valuation and price estimate. Below are some of the charts and data from the interactive dashboard.

&l;strong&g;Expect R&a;amp;D Expenses To Grow In Low Single Digits In 2018&l;/strong&g;

&l;a href=&q;http://dashboards.trefis.com/no-login-required/oDtgFxAH?fromforbesandarticle=how-sensitive-is-pfizer-to-rd-expense-changes&q; target=&q;_blank&q;&g;&l;img class=&q; wp-image-185958 size-full&q; src=&q;http://blogs-images.forbes.com/greatspeculations/files/2018/07/pfe2-e1530553110440.jpg?width=960&q; alt=&q;&q; data-height=&q;383&q; data-width=&q;394&q;&g;&l;/a&g;

&a;nbsp;

&l;/p&g;&l;div&g; Pfizer&a;rsquo;s R&a;amp;D expenditures as a percentage of revenues have increased from around 17.0% in 2011 to around 18.5% in 2017. However, the figure has declined slightly over the last three years. We believe that R&a;amp;D expenditure as a percentage of revenues will come back to its historical average of less than 18% in the coming years. In 2018, we forecast the figure to be around 18.4%. Given that we forecast an increase in Pfizer&a;rsquo;s overall revenues for 2018, led by its Oncology segment, this should translate into overall R&a;amp;D expenditures of nearly $7.8 billion, reflecting a slight increase over the prior year. Of late, several pharmaceutical companies, including Pfizer, have been focusing on a few specific therapeutic areas such as oncology. This is expected to streamline expenses and optimize R&a;amp;D spending. However, developing and bringing a new drug to the market is a long process involving several phases including identifying the compound and clinical trials, which is costly and can last for several years. With many drugs, such as Lyrica, Xeljanz, and Sutent facing patent expiry over the next few years, Pfizer has been investing prudently to grow its pharmaceutical pipeline, and this trend is likely to continue, at least in the near term. The company has around 7 new drugs under its phase 3 pipeline, including Dacomitinib, Talazoparib, Tanezumbab, and Rivipansel. The company is also testing some biosimilars for existing drugs. This could result in higher R&a;amp;D spending as well. A 2.5% increase in R&a;amp;D expenditures as a percentage of gross profit would translate into an approximately 5% decline in Pfizer&a;rsquo;s valuation and stock price estimate, as shown in the scenario on our &l;a href=&q;http://dashboards.trefis.com/no-login-required/oDtgFxAH?d=456616&a;amp;dt=79187b4dfbd492728c28295c464c17bdeadc1541&q; target=&q;_blank&q;&g;interactive dashboard analysis&l;/a&g;. &l;/div&g;

&l;div&g;&l;/div&g;

&l;div&g;What&a;rsquo;s behind Trefis? See How It&a;rsquo;s Powering New Collaboration and What-Ifs&l;/div&g;

&l;div&g;&l;/div&g;

&l;div&g;For &l;b&g;&l;a href=&q;https://www.trefis.com/trefis-technology&q; target=&q;_blank&q; rel=&q;noopener noreferrer&q; target=&q;_blank&q;&g;CFOs and Finance Teams&l;/a&g;&l;/b&g; | &l;b&g;&l;a href=&q;https://www.trefis.com/&q; target=&q;_blank&q; rel=&q;noopener noreferrer&q; target=&q;_blank&q;&g;Product, R&a;amp;D, and Marketing Teams&l;/a&g;&l;/b&g;&l;/div&g;

&l;div&g;&l;/div&g;

&l;div&g;&l;/div&g;

&l;div&g;&l;strong&g;&l;a href=&q;http://www.trefis.com/&q; target=&q;_blank&q; rel=&q;noopener noreferrer&q; target=&q;_blank&q;&g;More Trefis Research&l;/a&g;&l;/strong&g;&l;/div&g;

&l;div&g;&l;/div&g;

&l;div&g;&l;/div&g;

&l;div&g;Like our charts? Explore &l;a href=&q;https://dashboards.trefis.com/signupDashboard&q; target=&q;_blank&q; rel=&q;noopener noreferrer&q; target=&q;_blank&q;&g;example interactive dashboards&l;/a&g; and create your own.&l;/div&g;

&l;div&g;&l;/div&g;

&l;strong&g;

&l;/strong&g;

Wednesday, July 4, 2018

Golar LNG Partners (GMLP) Stock Rating Upgraded by ValuEngine

Golar LNG Partners (NASDAQ:GMLP) was upgraded by investment analysts at ValuEngine from a “sell” rating to a “hold” rating in a report issued on Monday.

Other analysts also recently issued reports about the company. BidaskClub upgraded Golar LNG Partners from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Zacks Investment Research downgraded Golar LNG Partners from a “hold” rating to a “sell” rating in a research report on Thursday, June 21st. B. Riley decreased their target price on Golar LNG Partners from $23.00 to $17.00 and set a “hold” rating on the stock in a research report on Friday, June 8th. Stifel Nicolaus decreased their target price on Golar LNG Partners from $25.00 to $21.00 and set a “buy” rating on the stock in a research report on Friday, June 1st. Finally, Bank of America decreased their target price on Golar LNG Partners from $26.00 to $24.00 and set a “buy” rating on the stock in a research report on Monday, March 5th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $21.80.

Get Golar LNG Partners alerts:

GMLP traded up $0.02 during trading on Monday, reaching $15.48. 217,573 shares of the stock were exchanged, compared to its average volume of 399,449. The company has a debt-to-equity ratio of 1.93, a quick ratio of 1.71 and a current ratio of 1.73. The company has a market cap of $1.08 billion, a price-to-earnings ratio of 8.23, a PEG ratio of 1.59 and a beta of 0.87. Golar LNG Partners has a 1 year low of $14.27 and a 1 year high of $23.46.

Golar LNG Partners (NASDAQ:GMLP) last posted its earnings results on Thursday, May 31st. The shipping company reported $0.21 EPS for the quarter, topping the Zacks’ consensus estimate of $0.09 by $0.12. The company had revenue of $74.21 million for the quarter, compared to the consensus estimate of $77.64 million. Golar LNG Partners had a return on equity of 16.74% and a net margin of 29.68%. analysts predict that Golar LNG Partners will post 1.22 EPS for the current fiscal year.

Golar LNG Partners announced that its Board of Directors has initiated a stock buyback plan on Monday, March 5th that authorizes the company to repurchase $25.00 million in outstanding shares. This repurchase authorization authorizes the shipping company to repurchase shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.

Several large investors have recently modified their holdings of GMLP. California Public Employees Retirement System lifted its position in shares of Golar LNG Partners by 1.8% in the fourth quarter. California Public Employees Retirement System now owns 154,810 shares of the shipping company’s stock valued at $3,530,000 after acquiring an additional 2,679 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of Golar LNG Partners by 2.1% in the fourth quarter. Wells Fargo & Company MN now owns 130,671 shares of the shipping company’s stock valued at $2,978,000 after acquiring an additional 2,631 shares in the last quarter. Raymond James Financial Services Advisors Inc. lifted its position in shares of Golar LNG Partners by 47.6% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 19,541 shares of the shipping company’s stock valued at $446,000 after acquiring an additional 6,300 shares in the last quarter. BlackRock Inc. lifted its position in shares of Golar LNG Partners by 67.1% in the fourth quarter. BlackRock Inc. now owns 150,648 shares of the shipping company’s stock valued at $3,434,000 after acquiring an additional 60,476 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its position in shares of Golar LNG Partners by 43.5% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 159,098 shares of the shipping company’s stock valued at $3,627,000 after acquiring an additional 48,191 shares in the last quarter. Institutional investors and hedge funds own 41.49% of the company’s stock.

About Golar LNG Partners

Golar LNG Partners LP owns and operates floating storage regasification units (FSRUs) and liquefied natural gas (LNG) carriers under long-term charters in Brazil, Indonesia, Jordan, Kuwait, and the United Arab Emirates. As of April 6, 2018, it had a fleet of six FSRUs and four LNG carriers. Golar GP LLC serves as the general partner of Golar LNG Partners LP.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Golar LNG Partners (NASDAQ:GMLP)

Monday, July 2, 2018

Will Trump Finally Turn His Trade Guns on the WTO?

LISTEN TO ARTICLE 5:14 SHARE THIS ARTICLE Facebook Twitter LinkedIn Email

President Donald Trump is following through on his campaign pledges to reshape the global trading system. Is the World Trade Organization his next target? With his administration renegotiating the North American Free Trade Agreement, and already out of the trade pact formerly known as the Trans-Pacific Partnership, the WTO stands as one of the last major, multilateral trade agreements or negotiations that Trump hasn’t disavowed.

1. What are Trump’s intentions on the WTO?

That’s unclear. Axios reported on June 29 that the president has repeatedly told top White House officials that he wants to withdraw the U.S. from the WTO. U.S. Treasury Secretary Steven Mnuchin quickly disputed the statement, calling the report “an exaggeration” during an interview on Fox Business Network.

2. What does the WTO do?

It’s an international body that negotiates, monitors and mediates trade rules among 164 members including the U.S., China, Russia and the European Union. Established in 1994 and based in Geneva, it has a goal of reducing obstacles to international trade. It has no authority over its members’ labor rules, antitrust laws, monetary policies or tax rules, so long as such policies do not distort or block trade.

3. What has Trump said about the WTO?

As a candidate, he said the WTO was a “disaster” and threatened to withdraw from the organization. In April 2017 Trump ordered a review of all U.S. trade deals, including its participation in the the WTO, to see if any harm national interests and should be revised or terminated. Trump has mentioned his distaste for the organization repeatedly, saying the WTO is “unfair” and “bad” to the U.S. in posts on Twitter. Robert Lighthizer, Trump’s trade chief, has said that a “slavish dedication” to WTO rules“makes very little sense.”

4. How has the WTO responded?

Cautiously. WTO Director-General Roberto Azevedo has repeatedly warned of the consequences of a global trade war. Last year, Azevedo said the biggest risk to the global trade order is one country taking unilateral action that causes a retaliatory, domino effect throughout the system. Since then, the announcement of U.S. plans to place tariffs on steel and aluminum imports received quick responses of retaliatory measures by other WTO members prompting Azevedo to issue a sharp warning in March: "An eye for an eye will leave us all blind and the world in deep recession. We must make every effort to avoid the fall of the first dominoes.”

5. Has the WTO weighed in on Trump’s tariffs?

Not yet, but it’s fielded objections. Six countries filed complaints to the WTO in response to the metals tariffs, accusing the U.S. of using the measures to protect the steel and aluminum industries from outside competition -- thus violating WTO rules. Lighthizer cites Article XXI of the GATT, which specifies WTO members are permitted to take action necessary to protect essential security interests, to justify the legality of recent metals tariffs.

6. What does the WTO do in a case like this?

Its dispute-settlement system aims to discourage nations from unilaterally raising tariffs or imposing other trade sanctions against one another. The goal is to prevent escalation that can lead to trade wars. The WTO first encourages members to resolve their disputes by seeking a settlement through informal discussions. If that’s not possible, the WTO’s dispute-settlement body will study the matter, issue a ruling and, if required, urge guilty parties to bring their laws into compliance. The threat of a true trade war escalates when countries intentionally bypass WTO rules and ignore its rulings to pursue unilateral tariffs or other restrictions.

7. Are WTO rules legally binding?

For the most part. Each member agrees to abide by the WTO’s various agreements and the individual terms accepted when it joins. That said, the U.S. agreed to join the organization on the condition that the WTO and its dispute system wouldn’t override its obligations and rights. The WTO’s primary legal authority is rooted in the General Agreement on Tariffs and Trade, also known as GATT, which aims to promote international trade in goods. The WTO also oversees certain rules related to trade in agriculture, services and intellectual property, among other issues.

8. What happens if a member ignores WTO dispute rulings?

The country that brought the complaint can ask the WTO to authorize retaliatory trade measures.

9. Could the U.S. withdraw from the WTO?

Yes, but it would be problematic for the U.S. and could leave its companies at a disadvantage. Other countries would be able to unilaterally raise tariffs on U.S. imports and impose burdensome requirements that prevent U.S. companies from competing abroad. The U.S. would also forfeit any ability to overturn unfair trade practices via the WTO dispute-settlement system.

The Reference ShelfA 2017 Bloomberg article outlined the Trump’s administration’s complaints on the global trading system.QuickTake explainers on free trade and Trump’s fears of U.S. trade deficits. Can Trump win a trade war with China?China should listen to U.S. complaints on trade, Michael Schuman writes in Bloomberg Opinion.

Friday, June 29, 2018

Analysts Expect Dixie Group Inc (DXYN) to Announce $0.02 Earnings Per Share

Dixie Group Inc (NASDAQ:DXYN) has been assigned an average broker rating score of 2.00 (Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy recommendation.

Brokers have set a twelve-month consensus target price of $5.00 for the company and are forecasting that the company will post $0.02 earnings per share for the current quarter, according to Zacks. Zacks has also given Dixie Group an industry rank of 243 out of 255 based on the ratings given to its competitors.

Get Dixie Group alerts:

A number of analysts recently issued reports on DXYN shares. ValuEngine cut Dixie Group from a “sell” rating to a “strong sell” rating in a research report on Thursday, May 3rd. Zacks Investment Research raised Dixie Group from a “strong sell” rating to a “hold” rating in a research report on Tuesday, May 1st.

Institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. lifted its position in Dixie Group by 25.1% during the 1st quarter. Russell Investments Group Ltd. now owns 603,820 shares of the textile maker’s stock worth $1,661,000 after acquiring an additional 120,979 shares during the period. Boston Partners lifted its position in Dixie Group by 16.2% during the 1st quarter. Boston Partners now owns 763,620 shares of the textile maker’s stock worth $2,100,000 after acquiring an additional 106,600 shares during the period. Wells Fargo & Company MN lifted its position in Dixie Group by 3.4% during the 1st quarter. Wells Fargo & Company MN now owns 1,813,701 shares of the textile maker’s stock worth $4,988,000 after acquiring an additional 60,229 shares during the period. Finally, Royce & Associates LP lifted its position in Dixie Group by 5.7% during the 4th quarter. Royce & Associates LP now owns 1,549,912 shares of the textile maker’s stock worth $5,967,000 after acquiring an additional 82,982 shares during the period. 61.87% of the stock is owned by institutional investors.

Shares of Dixie Group traded down $0.05, reaching $2.30, during trading hours on Friday, according to MarketBeat Ratings. The stock had a trading volume of 500 shares, compared to its average volume of 15,674. The stock has a market cap of $37.99 million, a PE ratio of -33.57 and a beta of 0.14. The company has a quick ratio of 0.85, a current ratio of 2.69 and a debt-to-equity ratio of 1.62. Dixie Group has a fifty-two week low of $2.20 and a fifty-two week high of $4.75.

Dixie Group (NASDAQ:DXYN) last announced its earnings results on Thursday, May 3rd. The textile maker reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). The firm had revenue of $98.86 million during the quarter, compared to analyst estimates of $99.70 million. Dixie Group had a negative net margin of 2.87% and a negative return on equity of 4.16%. sell-side analysts anticipate that Dixie Group will post 0.06 earnings per share for the current year.

Dixie Group Company Profile

The Dixie Group, Inc manufactures, markets, and sells floorcovering products for residential and commercial applications primarily in the United States. It offers residential carpets and custom rugs, specialty carpets and rugs, residential tufted broadloom and rugs, and broadloom and modular carpet tiles.

Get a free copy of the Zacks research report on Dixie Group (DXYN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Sunday, June 24, 2018

Should You Buy Red Hat After Its Post-Earnings Plunge?

Shares of Red Hat (NYSE:RHT) tumbled during after-hours trading on June 21, after the enterprise software company followed up�its first-quarter earnings beat with tepid guidance. Its revenue rose 20% annually to $813.5 million, beating expectations by about $6 million. Its non-GAAP net income climbed 28% to $133 million, or $0.72 per share, clearing estimates by $0.03.

But for the current quarter, Red Hat expects just 14% to 15% sales growth, compared to the consensus estimate of 18% growth. Its forecast for 5% non-GAAP EPS growth also missed expectations for 16% growth. Red Hat's full-year revenue forecast for 16% to 18% missed the consensus estimate of 19%, but its earnings guidance for 15% to 17% growth exceeded expectations.

Servers in a data center.

Image source: Getty Images.

Despite the recent pullback, Red Hat's stock remains up nearly 20% for the year, and it still isn't cheap, at over 40 times this year's earnings. So, is it time to sell Red Hat, or does this dip represent a long-term buying opportunity?

What does Red Hat do?

Red Hat provides open-source software products -- including Red Hat Enterprise Linux, the Red Hat Virtualization (RHV) platform, and JBoss middleware -- to enterprise customers. Most of Red Hat's software products are free, but it sells subscriptions for support, training, and integration services for those products.

Red Hat's subscription revenue grew 19% annually to $712 million last quarter and accounted for 87% of its top line. Within that total, its subscription revenues from infrastructure-related services rose 14% to $522 million, while revenues from application-development and emerging technology services rose 37% to $189 million.

Red Hat benefits from the rise of hybrid cloud deployments, in which large enterprises move part of their data to the public cloud while retaining some data in on-premise servers. It holds partnerships with Microsoft (NASDAQ:MSFT) and IBM (NYSE:IBM) in that market.

Red Hat integrates its OpenShift platform with Microsoft's Azure, the second largest cloud infrastructure platform in the world. That integration makes it easier for enterprise developers to shift between Azure, a public cloud platform, and on-premise environments. It also integrates OpenShift into IBM's software and cloud services, which helps Big Blue modernize its portfolio with Linux "containers" -- which isolate applications from the rest of the system.

A graphical representation of cloud computing.

Image source: Getty Images.

During the quarter, Red Hat reported a 48% year-over-year increase in deals worth�over $1 million -- and 70% of those deals included one or more components from its higher-growth application-development and emerging technologies unit. Mid-market deals worth over $250,000 rose 138% annually. Red Hat also added over 100 new customers to its Linux container platform OpenShift, as its subscribers for Ansible, which automates software tasks, jumped about 70% to over 1,000.

Understanding the tailwinds and headwinds

Red Hat's core business is well-poised for growth as the hybrid cloud market expands. The company's unique business model and partnerships with enterprise giants like Microsoft and IBM give it plenty of room to upsell and cross-sell other services.

Last quarter, 25 of Red Hat's largest deals that were up for renewal renewed in aggregate at over 120% of their previous values. 70% of its cross-selling deals also cleared $1 million.

Yet two main headwinds could throttle Red Hat's near-term growth. First, Red Hat expects a strengthening dollar to reduce its full-year reported revenues by $50 million. Second, an ongoing shift from physical deployments to container environments is throttling Red Hat's middleware growth. Red Hat partly offsets that softer growth with the stronger growth of its emerging technologies unit, but it's still causing its sales and earnings growth to decelerate.

Should you buy Red Hat on the dip?

Red Hat is a compelling long-term play on the hybrid cloud and the modernization of IT systems. Unfortunately, the stock's valuations aren't supported by its growth forecasts. Therefore, investors should wait for the stock to drop to lower levels before starting a position.

Tuesday, June 19, 2018

Bandwidth Inc (BAND) Director Henry R. Kaestner Sells 37,500 Shares

Bandwidth Inc (NASDAQ:BAND) Director Henry R. Kaestner sold 37,500 shares of Bandwidth stock in a transaction dated Friday, June 15th. The shares were sold at an average price of $39.27, for a total transaction of $1,472,625.00. The sale was disclosed in a document filed with the SEC, which is available at this link.

Shares of Bandwidth opened at $39.87 on Tuesday, Marketbeat Ratings reports. Bandwidth Inc has a twelve month low of $18.05 and a twelve month high of $40.83. The stock has a market cap of $698.68 million and a PE ratio of 81.37.

Get Bandwidth alerts:

Bandwidth (NASDAQ:BAND) last issued its earnings results on Wednesday, May 2nd. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.02. The business had revenue of $53.00 million for the quarter, compared to analyst estimates of $47.19 million. During the same quarter last year, the firm posted $0.22 earnings per share. Bandwidth’s revenue was up 33.8% on a year-over-year basis. analysts anticipate that Bandwidth Inc will post -0.14 earnings per share for the current year.

Hedge funds have recently made changes to their positions in the stock. Barclays PLC bought a new position in Bandwidth during the 1st quarter valued at about $262,000. Northern Trust Corp bought a new position in Bandwidth during the 1st quarter valued at about $263,000. Wedbush Securities Inc. bought a new position in Bandwidth during the 1st quarter valued at about $269,000. Virtu Financial LLC bought a new position in Bandwidth during the 4th quarter valued at about $277,000. Finally, Archon Capital Management LLC bought a new position in Bandwidth during the 1st quarter valued at about $531,000. 21.03% of the stock is owned by hedge funds and other institutional investors.

Several brokerages have recently weighed in on BAND. KeyCorp reiterated a “buy” rating on shares of Bandwidth in a research report on Wednesday, May 2nd. Robert W. Baird reiterated an “outperform” rating and set a $30.00 target price (up from $28.00) on shares of Bandwidth in a research report on Thursday, February 22nd. ValuEngine upgraded shares of Bandwidth from a “sell” rating to a “hold” rating in a research report on Monday, April 2nd. Morgan Stanley lifted their target price on shares of Bandwidth from $28.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, May 3rd. Finally, Dougherty & Co set a $40.00 target price on shares of Bandwidth and gave the company a “buy” rating in a research report on Tuesday, April 24th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $38.00.

Bandwidth Company Profile

Bandwidth Inc operates as a cloud-based software-powered communications platform-as-a-service (CPaaS) provides in the United States. The company operates through two segments, CPaaS and Other. Its platform enables enterprises to create, scale, and operate voice or text communications services across mobile application or connected device.

Sunday, May 27, 2018

Pendal Group Ltd Increases Position in Walmart Inc (WMT)

Pendal Group Ltd increased its stake in Walmart Inc (NYSE:WMT) by 10.7% in the 1st quarter, HoldingsChannel reports. The fund owned 208,501 shares of the retailer’s stock after buying an additional 20,101 shares during the quarter. Pendal Group Ltd’s holdings in Walmart were worth $18,550,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Wunderlich Capital Managemnt lifted its stake in Walmart by 2.4% in the fourth quarter. Wunderlich Capital Managemnt now owns 20,868 shares of the retailer’s stock worth $2,061,000 after purchasing an additional 496 shares during the last quarter. CHICAGO TRUST Co NA lifted its stake in Walmart by 17.3% in the fourth quarter. CHICAGO TRUST Co NA now owns 3,393 shares of the retailer’s stock worth $335,000 after purchasing an additional 500 shares during the last quarter. Covington Capital Management lifted its stake in Walmart by 1.6% in the fourth quarter. Covington Capital Management now owns 31,888 shares of the retailer’s stock worth $3,149,000 after purchasing an additional 500 shares during the last quarter. TCI Wealth Advisors Inc. raised its stake in shares of Walmart by 8.5% during the fourth quarter. TCI Wealth Advisors Inc. now owns 6,467 shares of the retailer’s stock valued at $639,000 after acquiring an additional 505 shares during the last quarter. Finally, Douglass Winthrop Advisors LLC raised its stake in shares of Walmart by 1.4% during the fourth quarter. Douglass Winthrop Advisors LLC now owns 40,365 shares of the retailer’s stock valued at $3,986,000 after acquiring an additional 539 shares during the last quarter. Institutional investors own 29.77% of the company’s stock.

Get Walmart alerts:

Several equities analysts have recently commented on WMT shares. Royal Bank of Canada lowered their price objective on shares of Walmart to $168.00 and set a “market perform” rating for the company in a research note on Thursday, May 10th. Vetr raised shares of Walmart from a “buy” rating to a “strong-buy” rating and set a $110.28 price objective for the company in a research note on Tuesday, February 20th. Goldman Sachs Group reaffirmed a “buy” rating and set a $113.00 price objective on shares of Walmart in a research note on Friday, February 16th. Credit Suisse Group set a $102.00 price objective on shares of Walmart and gave the company a “hold” rating in a research note on Tuesday, May 1st. Finally, Zacks Investment Research raised shares of Walmart from a “hold” rating to a “buy” rating and set a $98.00 price objective for the company in a research note on Friday, May 4th. Nineteen equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and two have given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $96.56.

NYSE:WMT opened at $82.85 on Friday. Walmart Inc has a 52 week low of $73.13 and a 52 week high of $109.98. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.20 and a current ratio of 0.73. The company has a market cap of $246.97 billion, a PE ratio of 18.74, a PEG ratio of 2.89 and a beta of 0.54.

Walmart (NYSE:WMT) last posted its quarterly earnings results on Thursday, May 17th. The retailer reported $1.14 EPS for the quarter, beating the Zacks’ consensus estimate of $1.12 by $0.02. Walmart had a net margin of 1.77% and a return on equity of 17.16%. The firm had revenue of $122.69 billion for the quarter, compared to analysts’ expectations of $119.29 billion. During the same quarter in the prior year, the company posted $1.00 earnings per share. The business’s revenue for the quarter was up 4.4% on a year-over-year basis. equities analysts predict that Walmart Inc will post 4.86 earnings per share for the current fiscal year.

Walmart Profile

Walmart Inc engages in the retail and wholesale operations in various formats worldwide. The company operates through three segments: Walmart U.S., Walmart International, and Sam's Club. It operates supercenters, supermarkets, hypermarkets, warehouse clubs, cash and carry stores, discount stores, drugstores, and convenience stores; membership-only warehouse clubs; e-commerce Websites, such as walmart.com, jet.com, hayneedle.com, shoes.com, moosejaw.com, modcloth.com, bonobos.com, and samsclub.com; and mobile commerce and voice-activated commerce applications.

Want to see what other hedge funds are holding WMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Walmart Inc (NYSE:WMT).

Institutional Ownership by Quarter for Walmart (NYSE:WMT)

Saturday, May 26, 2018

Best Biotech Stocks To Invest In Right Now

tags:KRO,UL,ETE,

As this article pertains mainly to Advaxis, Inc. (ADXS), I think it's very important to state from the outset that, unlike most of the stocks that I write and have written about, I do own shares in this company, and I likely will acquire more in the near future. I don't intend that statement as an endorsement of ADXS, and it is not because I think other companies are necessarily a worse investment. Please take this potential for bias into account as you read this article. Thank you.

Introduction

ADXS is a developmental-stage biotech focused on the development of attenuated listeria-based immunotherapy for the treatment of solid tumors. Most notably, the company is in late-stage clinical development for cervical cancer.

In 2017, ADXS has had a lot of ups and downs. Clinically, it has yet to have any sort of bad news, in stark contrast with, say, 2015, when the FDA placed a clinical hold on its trials due to potential safety concerns (later deemed unfounded, and the trials restarted). But on the business end of things, ADXS has had some challenges.

Best Biotech Stocks To Invest In Right Now: Kronos Worldwide Inc(KRO)

Advisors' Opinion:
  • [By Maxx Chatsko]

    Shares of�Kronos Worldwide (NYSE:KRO) plunged on Wednesday after the company announced first-quarter 2018 results. The titanium dioxide manufacturer reported strong growth compared to the year-ago period thanks to the continued surge in selling prices. Revenue was up 16% and net income nearly doubled relative to the first quarter of 2017. How can Wall Street be displeased with that?�

Best Biotech Stocks To Invest In Right Now: Unilever PLC(UL)

Advisors' Opinion:
  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers Aceto Corporation (NASDAQ: ACET) fell 41.9 percent to $4.30 in pre-market trading. ACETO board disclosed that it is taking proactive steps to address business and financial challenges. Canaccord Genuity downgraded Aceto from Buy to Sell. Helios and Matheson Analytics Inc. (NASDAQ: HMNY) fell 25.3 percent to $2.86 in pre-market trading after reporting an ATM offering of $150 million. Pier 1 Imports, Inc. (NYSE: PIR) fell 17.4 percent to $2.86 in pre-market trading after reporting a fourth quarter sales miss. Comps were down 7.5 percent in the quarter. Sleep Number Corporation (NASDAQ: SNBR) fell 12.4 percent to $32.00 in pre-market trading following a first quarter earnings miss. Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) fell 10.2 percent to $11.90 in pre-market trading on news of $125 million convertible debt offering. Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) shares fell 8 percent to $8.02 in pre-market trading after dropping 2.02 percent on Wednesday. Exponent, Inc. (NASDAQ: EXPO) shares fell 5.6 percent to $80 in pre-market trading. Lumentum Holdings Inc. (NASDAQ: LITE) shares fell 4.8 percent to $60.00 in pre-market trading after rising 1.78 percent on Wednesday. vTv Therapeutics Inc. (NASDAQ: VTVT) fell 4.6 percent to $2.10 in pre-market trading after surging 84.87 percent on Wednesday. Taiwan Semiconductor Manufacturing Company Limited (NYSE: TSM) shares fell 4.5 percent to $40.07 in pre-market trading after the company reported Q1 results. Align Technology, Inc.. (NASDAQ: ALGN) fell 3.5 percent to $267.40 in pre-market trading after rising 1.61 percent on Wednesday. Transocean Ltd. (NYSE: RIG) shares fell 3.5 percent to $12 in pre-market trading after the company issued quarterly fleet status report. GoPro, Inc. (NASDAQ: GPRO) fell 3.2 percent to $4.90 in pre-market trading. Unilever PLC (NYSE: UL) fell 2.6 percent to $54.73 in pre-market
  • [By Max Byerly]

    News coverage about Unilever (NYSE:UL) has been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Unilever earned a news impact score of 0.12 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 47.0118624662366 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

  • [By Isaac Pino, CPA]

    Dollar Shave Club, bought by Unilever (NYSE:UL) in 2016, offers membership as low as $5. Again, the margins may be thin on the products -- just like at Costco -- but that's made up by what hopefully becomes a longer, deeper relationship with the customer.

  • [By Shane Hupp]

    Church & Dwight (NYSE: CHD) and Unilever (NYSE:UL) are both large-cap consumer staples companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.

  • [By Max Byerly]

    Sandy Spring Bank increased its position in shares of Unilever plc (NYSE:UL) by 627.6% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,820 shares of the company’s stock after purchasing an additional 3,295 shares during the period. Sandy Spring Bank’s holdings in Unilever were worth $212,000 at the end of the most recent reporting period.

Best Biotech Stocks To Invest In Right Now: Energy Transfer Equity, L.P.(ETE)

Advisors' Opinion:
  • [By Matthew DiLallo]

    One reason investors are worried that Energy Transfer might need to reduce its distribution is that the company barely generates enough cash flow to support it without the help of its parent Energy Transfer Equity (NYSE:ETE). In 2017, Energy Transfer Partners produced $4.19 billion in distributable cash flow and would have paid out $4.15 billion to investors if it wasn't for the fact that Energy Transfer Equity relinquished its rights to $656 million of that cash. While that support boosted the distribution coverage ratio from a tight 1.0 times to a more comfortable 1.2 times, it was only a temporary fix since Energy Transfer Equity's support will diminish significantly in 2018 before declining further in 2019 and 2020.

  • [By Matthew DiLallo]

    Management teams tend to be very coy about what they're working on behind closed doors. Energy Transfer Equity's (NYSE:ETE) leadership, on the other hand, was very transparent about what's going on behind the scenes during the company's first-quarter conference call. They openly answered analysts' questions, which provided investors with an interesting glimpse into what's ahead.

  • [By Matthew DiLallo]

    Like last quarter, Energy Transfer Partners delivered strong earnings and cash flow growth. Because of that, the company was able to cover its jaw-dropping 12.4%-yielding distribution by a healthy 1.15 times. That slight decline from the year-ago quarter was caused by parent company�Energy Transfer Equity (NYSE:ETE)�significantly reducing its support. For a better comparison, the coverage ratio would have still been a solid 1.1 in this year's first quarter without any assistance from Energy Transfer Equity, while it would have been a worrisome 0.98 in the year-ago period without the parent company's help. That improvement is�exactly what investors wanted to see this quarter.

  • [By Stephan Byrd]

    D.A. Davidson & CO. reduced its stake in Energy Transfer Equity (NYSE:ETE) by 10.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 46,328 shares of the pipeline company’s stock after selling 5,550 shares during the period. D.A. Davidson & CO.’s holdings in Energy Transfer Equity were worth $658,000 at the end of the most recent quarter.

Thursday, May 24, 2018

Samsonite Tumbles After Short Seller Questions Accounting

Samsonite International SA, the world’s largest branded-luggage maker, tumbled the most since 2012 after short-seller Blue Orca Capital questioned the company’s accounting and corporate governance.

Samsonite concealed slowing growth with debt-funded acquisitions and inflated profit margins with dubious accounting linked to its takeovers, Blue Orca, founded by former Glaucus Research Group research director Soren Aandahl, alleged in a report on Thursday. A spokeswoman for Samsonite, whose roots trace back to the early 1900s, said she couldn’t immediately comment on the report.

#lazy-img-328012261:before{padding-top:56.25%;}

Shares of the Hong Kong-listed company slumped 9.8 percent to HK$30.70 before trading was halted at 11:18 a.m. local time. Blue Orca said the stock is worth HK$17.59.

The short-seller’s allegations center on a Samsonite growth strategy that has mostly been applauded by investors and sell-side analysts in recent years. The luggage maker’s acquisitions, which include rival Tumi Holdings Inc. and online retailer eBags Inc., helped boost Samsonite’s net sales to a record in 2017 and lifted the stock to a 16 percent gain in the 12 months before today’s slump. The average share-price target compiled by Bloomberg on Thursday implied a 26 percent advance over the next year.

Read more: Samsonite Eyes Handbag Brand After $1.8 Billion Tumi Deal

Blue Orca’s call for the stock to extend Thursday’s drop by another 43 percent is much more pessimistic than even the most bearish sell-side estimate. Among other allegations Blue Orca cited for its outlook: questionable related-party transactions between Samsonite and Indian entities controlled by Chief Executive Officer Ramesh Tainwala and his family, and a revolving door of auditors at the luggage maker’s South Asia unit.

Samsonite’s revenue from India and the Association of Southeast Asian Nations accounted for less than 10 percent of the company’s global sales and profit last year, according to Catherine Lim, a Bloomberg Intelligence analyst in Singapore. She noted that corporate disclosures are generally less transparent in emerging Asian markets and that related-party transactions aren’t uncommon.

“Samsonite has to date delivered on its articulated strategy since its public listing in 2011 of fueling growth via acquisitions in my view,” Lim said.

The Samsonite report ends a lengthy period of quiet from activist short sellers in Hong Kong, where a broad market rally has caused many bearish wagers to backfire. Fullshare Holdings Ltd., Aandahl’s last Hong Kong-listed target, has advanced 29 percent since he said (via a Glaucus report) in April 2017 that the stock was “poised to crash.” Shortly thereafter, Fullshare denied Aandahl’s allegations and won a show of support from state-owned China Citic Bank Corp. in the form of a $1.45 billion credit line.

Still, Aandahl has notched several big wins at Glaucus in recent years. His successful targets in Asia include Hong Kong-listed Tech Pro Technology Development Ltd., which tumbled 86 percent in a single day after a Glaucus report in July 2016, and Blue Sky Alternative Investments Ltd., an Australian asset manager that has dropped 77 percent since Glaucus targeted the company in March.

Aandahl announced the founding of Blue Orca this month after parting ways with Glaucus co-founder Matt Wiechert.

— With assistance by Daniela Wei

(Updates with stock halt in third paragraph and analyst quotes from sixth paragraph.) LISTEN TO ARTICLE 3:10 Share Share on Facebook Post to Twitter Send as an Email Print

Wednesday, May 23, 2018

Worldpay Inc (WP) Executive Chairman and Co-CEO Charles Drucker Sold $7 million of Shares

Executive Chairman and Co-CEO of Worldpay Inc (NYSE:WP) Charles Drucker sold 85,000 shares of WP on 05/21/2018 at an average price of $82.2 a share. The total sale was $7 million.

Worldpay Inc is a payment processing company that provides integrated technology platform. It offers suite of payment processing services through a single provider, including e-commerce and mobile devices. Worldpay Inc has a market cap of $25.3 billion; its shares were traded at around $80.92 with a P/E ratio of 312.84 and P/S ratio of 3.67. Worldpay Inc had annual average EBITDA growth of 11.40% over the past five years.

CEO Recent Trades:

Executive Chairman and Co-CEO Charles Drucker sold 85,000 shares of WP stock on 05/21/2018 at the average price of $82.2. The price of the stock has decreased by 1.56% since.

CFO Recent Trades:

CFO Stephanie Ferris sold 7,790 shares of WP stock on 05/16/2018 at the average price of $80.92. The price of the stock has decreased by 0% since.

For the complete insider trading history of WP, click here

.

Tuesday, May 22, 2018

Sohu.com Inc (SOHU) CEO Charles Zhang Bought $1.1 million of Shares

CEO of Sohu.com Inc (NASDAQ:SOHU) Charles Zhang bought 30,000 shares of SOHU on 05/18/2018 at an average price of $36.23 a share. The total cost of this purchase was $1.1 million.

Sohu.com Inc is a Chinese online media, search and game service group. The company provides comprehensive online products and services on PCs and mobile devices in the People's Republic of China. Sohu.com Inc has a market cap of $1.4 billion; its shares were traded at around $36.08 with and P/S ratio of 0.72.

CEO Recent Trades:

CEO, 10% Owner Charles Zhang bought 30,000 shares of SOHU stock on 05/18/2018 at the average price of $36.23. The price of the stock has decreased by 0.41% since.CEO, 10% Owner Charles Zhang bought 20,000 shares of SOHU stock on 05/17/2018 at the average price of $36.78. The price of the stock has decreased by 1.9% since.CEO, 10% Owner Charles Zhang bought 16,500 shares of SOHU stock on 05/15/2018 at the average price of $36.53. The price of the stock has decreased by 1.23% since.CEO, 10% Owner Charles Zhang bought 20,000 shares of SOHU stock on 05/11/2018 at the average price of $36.03. The price of the stock has increased by 0.14% since.CEO, 10% Owner Charles Zhang bought 100,000 shares of SOHU stock on 05/09/2018 at the average price of $35.34. The price of the stock has increased by 2.09% since.

Directors and Officers Recent Trades:

10% Owner Group Ltd Photon bought 30,000 shares of SOHU stock on 05/18/2018 at the average price of $36.23. The price of the stock has decreased by 0.41% since.10% Owner Group Ltd Photon bought 20,000 shares of SOHU stock on 05/17/2018 at the average price of $36.78. The price of the stock has decreased by 1.9% since.10% Owner Group Ltd Photon bought 16,500 shares of SOHU stock on 05/15/2018 at the average price of $36.53. The price of the stock has decreased by 1.23% since.10% Owner Group Ltd Photon bought 20,000 shares of SOHU stock on 05/11/2018 at the average price of $36.03. The price of the stock has increased by 0.14% since.10% Owner Group Ltd Photon bought 100,000 shares of SOHU stock on 05/09/2018 at the average price of $35.34. The price of the stock has increased by 2.09% since.

For the complete insider trading history of SOHU, click here

.

Monday, May 21, 2018

Blue Apron Partners With Costco, but That Doesn't Make Its Stock a Buy

Blue Apron (NYSE:APRN) is making a real effort to turn around its business by making its meal kits available to more consumers. As part of that push, the company will be providing meal kits to�Costco (NASDAQ:COST), the first such agreement since announcing it would no longer be delivery-only.

Unfortunately, it's not a cure-all for Blue Apron, which has struggled to grow its subscriber base. By selling meal kits in supermarkets and hoping consumers decide to try delivery, it becomes another commoditized product that still has to deal with the uneconomic value proposition its service offers.

Blue Apron meal kit

Selling Blue Apron meal kits in grocery stores makes them a commodity product. Image source: Blue Apron.

Customers don't come cheap

First-quarter revenue tumbled 20% year over year to $198 million as the number of customers and orders placed dropped yet again, while losses narrowed to $31.7 million, or $0.17 per share. It did, however, see a pick-up sequentially in the number of customers on the books, the orders they made, and revenue per customer.

The problem remains that customer acquisition is expensive. Blue Apron had ramped up its marketing ahead of its IPO last year to generate buzz about its growth potential, but after going public,�cut marketing costs. Its metrics crashed across the board as a result, and it's had to raise spending again to build up its customer counts.

CEO Brad Dickerson said the meal kit delivery service "began to methodically reaccelerate marketing late last year" which caused its marketing spend to rise 56% from the fourth quarter to $39.3 million, even though that's 39% less than a year ago.

So it picked up 40,000 more customers in the quarter at a cost of $14.1 million in extra marketing, suggesting each new member cost around $352. With revenue per customer at $250 each, that's not sustainable, particularly as order rates fall the longer a customer remains. Sure, not every marketing dollar spent went to new customer acquisition, but it shines a light on how difficult and costly it is to get people to try meal kit delivery and explains why Blue Apron moved into the grocery store.

Crowded shelves

Meal kits do provide a level of convenience and unique meal selection opportunities, but delivery is not for everyone. Not many people can afford the $60 to $80 a week it would cost to have a couple of Blue Apron meals delivered, but putting meal kits in grocery stores makes it easier for customers to discover Blue Apron products, even if they aren't converted to the delivery model.

Yet Blue Apron is not alone in making meal kits available in supermarkets. Rivals such as Hello Fresh are doing it, too, while Albertson's got the movement rolling when it purchased Plated to offer its kits in-store. Since then, Walmart, Kroger, and just about every other large, national chain has made them available in their stores, whether from a national manufacturer or their own store brands. Amazon.com also features them in its grocery section.

This means that other than the brand status that comes from buying Blue Apron at Costco, the meal kit delivery service is bringing nothing special to the table. It's become just another package available to purchase -- if you shop at Costco for groceries.

Blue Apron stock still not worth the cost

Moreover, Costco only has 740 stores in its portfolio, a far cry from the thousands of locations Walmart and Kroger boast. Certainly, Blue Apron doesn't plan to make Costco the sole arbiter of its future growth plans, but finding grocers with scale to assist that strategy becomes increasingly difficult.

Shares of Blue Apron have lost nearly three quarters of their value since the IPO, and though the stock sells at just a fraction of company sales, the meal kit service hasn't proved it's capable of earning a premium. As it becomes another me-too product by moving into supermarkets, its costly legacy business is still the bulk of revenue at the moment, and there's nothing to argue it deserves a premium yet, either.

However, the Costco initiative is a necessary step to experiment and grow distribution, so feel free to pick up its meal kits while you're out shopping. Just leave its stock on the shelf.

Saturday, May 19, 2018

Canadian Solar (CSIQ) Q1 2018 Earnings Conference Call Transcript

Logo of jester cap with thought bubble with words 'Fool Transcripts' below it

Image source: The Motley Fool.

Canadian Solar (NASDAQ:CSIQ) Q1 2018 Earnings Conference CallMay. 16, 2018 8:00 a.m. ET

Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

Operator

Ladies and gentlemen, thank you for standing by. Welcome to Canadian Solar's first-quarter 2018 earnings conference call. My name is Yvonne, and I will be your operator for today. [Operator instructions] As a reminder, this conference is being recorded for replay purposes.

I would now like to turn the call over to Mary Ma with Canadian Solar's IR department. Please go ahead.

Mary Ma -- Investor Relations

Thank you, operator, and welcome, everyone, to Canadian Solar's first-quarter 2018 earnings conference call. Joining us today on the call are Dr. Shawn Qu, our chairman and chief executive officer, and Dr. Huifeng Chang, our senior vice president and chief financial officer.

Before we begin, may I remind our listeners that management's prepared remarks today will contain forward-looking statements, which are subject to risks and uncertainties. And management may make additional forward-looking statements in response to your questions. Therefore, the company claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act of 1995. Actual results may differ from management's current expectations.

And therefore, we refer you to a more detailed discussion of the risks and uncertainties in the company's annual report on Form 20-F filed with the Securities and Exchange Commission. In addition, any projections as to the company's future performance represent management's estimates as of today's call. Canadian Solar assumes no obligation to update these projections in the future, unless otherwise required by applicable law. At this time, I would like to turn the call over to our chairman and CEO, Dr.

Shawn Qu. Shawn, please go ahead.

Shawn Qu -- Chairman and Chief Executive Officer

Thank you, Mary. We appreciate everyone taking the time to join us today. We are pleased with our results for the first quarter. Both module shipments and net revenue for the quarter exceeded our guidance.

We have made progress on the monetization of our global solar project asset in the quarter. The net revenue from the solar energy and total solutions business as a percentage of the total net revenue reached a record-high of 64.2%. Despite our encouraging results, we did see a slowdown in the solar module demand in the first quarter, partially due to the typical seasonality. However, the Section 201 import duty decision by the U.S.

government also had a major impact. In addition, many solar project developers in India were waiting for definitive decision from an anti-dumping trade case launched against solar modules from China and a safeguard case similar to that in the U.S. We believe our commitment to technology, our strategy of steady, conservative investments gives us a competitive advantage to weather the turmoil. I'm happy to report that we're on track in our shift from the PIII to PIV technology.

The PIV technology, combining diamond wire-saw wafering plus silicon cell processing and PERC cell technology, can further reduce manufacturing cost, will increase the multi-crystalline solar module efficiency. We are about to ramp up production of multi-busbar cells and modules, which will gradually replace all our 5 busbar cells. The multi-buffer cells can further increase module efficiency and reduce manufacturing cost. Besides our high-power, high-efficiency HDM module based on the latest Mono-PERC technology help us to gain market share in premium markets such as Japan.

On the energy business side, we continue to execute and are encouraged by our achievements in project monetization. We sold 482 megawatts of solar power assets in Q1. The highlight is the transaction to sell 3 solar power plants in the U.S. totaling 309 megawatts to KEPCO.

Another highlight was the sales of 141 megawatts of solar power plant in the U.K. to Greencoat Capital. Demand remains strong for our solar projects, given the high quality of our development and EPC work. We expect additional sales in 2018 as we work to get an attractive return for our company and shareholders and redeploy the capital into new opportunities.

One of the more recent transactions was the sale of our 80.6-megawatt Guimarania solar project in Brazil to Global Power Generation, which we completed in April. Our portfolio of solar power plants in operation totaled 948 megawatts with an estimated resale value of U.S. $1.1 billion at the end of April. As part of our strategy to redeploy capital, we further expanded our global late-stage project pipeline and diversified geographically into Australia, Austria, and Argentina.

These are some of the developing markets where the next phase of industry growth is expected. Our global footprint is directly aligned with these developing markets, giving us a competitive advantage and valuable head-start. We have been investing in this market and building a foundation through brand awareness for several years now. For example, on Monday, we announced we secured an 8-megawatt project in South Korea.

And in March, we acquired a 97.6-megawatt solar project in Argentina. In April, we won three solar projects totaling 364 megawatts in Brazil's A-4 auction. Our late-stage solar power project pipeline increased to 2.3 gigawatts, including those in construction at the end of April. Now let me comment on our guidance for Q2 2018.

We currently expect total Q2 module shipment to be in the range of approximately 1.5 to 1.6 gigawatts, including 100 megawatts of shipments to our own utility-scale solar projects. Revenue for the second quarter of 2018 is expected to be in the range of U.S. $690 million to U.S. $730 million with gross margin expected to be between 20% to 22%.

Let me now turn the call over to our CFO, Huifeng Chang, for a more detailed review of our result for the first quarter. Huifeng, please go ahead.

Huifeng Chang -- Chief Financial Officer

Thank you, Shawn. Net revenue for the first quarter of 2018 was $1.42 billion, up 28.5% sequentially and up 110.5% compared to the year-ago period. Gross profit in Q1 was $143.9 million, compared to $218.6 million in Q4. Gross margin in Q1 was 10.1%, compared to 19.7% in Q4.

The sequential decrease was primarily due to low margin associated with the 309 megawatts of U.S. solar power plants sold to KEPCO, combined with higher blended module manufacturing costs with a partial offset from increased module average selling price in the first quarter of 2018. We expect a considerable improvement in Q2 with guidance in the range of 20% to 22%. Total operating expenses was $65.7 million in Q1, compared to $88.4 million in Q4.

Income from operations was $78.2 million in Q1, compared to $130.2 million in Q4. Operating margin was 5.5% in Q1, compared to 11.7% in Q4. Foreign exchange loss in Q1 was $8.5 million, compared to foreign exchange loss of $9.5 million in Q4. We recorded a gain on change in fair value of derivatives of $4.5 million in Q1, compared to a gain of $7.6 million in Q4.

Income tax expense in Q1 was $4.1 million, compared to income tax expense of $28.9 million in Q4. Net income attributable to Canadian Solar shareholders for Q1 was $43.4 million, or $0.72 per diluted share, compared to net income of $61.4 million, or $1.01 per diluted share, in Q4. Moving on to the balance sheet. At the end of Q1, our balance of cash and cash equivalents was $567.4 million, compared to $561.7 million at the end of Q4.

Our restricted cash balance was $624.4 million at the end of Q1, compared to $628.5 million at the end of Q4. Trade accounts receivable balance was $354.3 million at the end of Q1, down from $358.1 million at the end of Q4. Accounts receivable turnover was 26 days in Q1 2018, compared to 38 days in Q4 2017. Inventories at the end of Q1 2018 were $414.1 million, compared to $346.1 million at the end of Q4 2017.

Inventory turnover was 28 days in Q1 2018, compared to 35 days in the first quarter of 2017. Short-term borrowings at the end of Q1 totaled $1.86 billion, compared to $1.96 billion at the end of Q4. Long-term borrowings at the end of Q4 -- Q1 was $328.1 million, compared to $404.3 million at the end of Q4. Total debt at the end of the first quarter of 2018 were approximately $2.45 billion, of which $785.7 million was nonrecourse.

Senior convertible debt outstanding totaled $126.7 million at the end of Q1, compared to $126.5 million at the end of Q4. Short-term borrowings and long-term borrowings directly related to utility-scale projects, which includes $708.4 million of nonrecourse borrowings, totaled $1.12 billion at the end of Q1, compared to $1.38 billion at the end of Q4. The value of our build-to-sell project assets at the end of Q1 was $1.1 billion, compared to $1.9 billion at the end of Q4 2017. We are pleased with our significant success in monetizing our solar power assets globally.

We are working to secure approval for the sale of 3 other U.S. solar projects totaling 399 megawatts with the potential to close the deal in the coming months. Our continued success actions are enhancing our balance sheet and allowing us to redeploy our capital to support the profitable growth of our business and to build value for shareholders. With that, I would now like to open the call to your questions.�Operator?

Questions and Answers:

Operator

Ladies and gentlemen, we will now begin the question-and-answer session. [Operator instructions] Our first question comes from the line of Colin Rusch from Oppenheimer. Please ask the question.

Colin Rusch -- Oppenheimer & Company -- Analyst

Thanks so much. Shawn, you've gone through a lot of these cycles in the past with the policy changes. And looking at what's going on in India, navigating the U.S. market, how do you think about incremental capacity and where it goes and how you're going to manage that as you go through the balance of this year? India's obviously been an important market for folks just as a kind of a backstop for volumes.

But what's your expectation and thought process and decision-making process as we go through the balance of this year and meeting all of the needs of these markets?

Shawn Qu -- Chairman and Chief Executive Officer

Yes, Colin, it's a good question. I have gone through several cycles like this. But every cycle is different. For example, this time, the U.S.

Section 201 trade decision, it immediately slowed down the new module shipments and projects in the U.S. In fact, it's quite dramatic. So I guess people already have commented on that. Some of the comments really is that there must have already been quite significant module inventory in the U.S.

shipped in before the Section 201 decision. So probably now all the distributors are just working through those products. Now India is an interesting phenomenon. It looks like the module importers were waiting because they didn't want to be caught with the tariff decision when a module is on the water.

And that's the common [Inaudible]. But if you think about it, how can a developer, if they already have product in hand, how can so many developers wait for three months, four months [Inaudible]?�So that's like just every cycle, it seems, is somehow different. Now your question on the capacity. Well, we do see capacity like we think the capacity along the value chain is not level.

It looks like, at this moment, there is more of a supply demand balance on polysilicon side. But that might -- that will probably start to change moving into the second half of this year. Now Canadian Solar hasn't touched the polysilicon yet. I guess we will continue this practice that we'll leave the polysilicon to the polysilicon suppliers.

And then on the Indian wafers, we have seen some significant announcements in India, especially the monocrystalline silicon expansions. So we try to avoid that. So from the capacity trend, which we updated in this earnings call, you can see that we are still quite conservative in terms of the India capacity. It looks like the solar cell, especially the high-efficiency solar cell, still -- that supply demand is well-balanced.

And that's why we are adding some capacity with our proprietary cell technologies, which is multi-crystalline-focused PIV technology, which combine the black silicon with the PERC technologies and also the bifacial solar cells. So that's where we'll add some capacity. And then on the module side, somehow the module capacity announcement is not that scaling as to India. So we're also adding some module capacity.

But we only add the module capacity with advanced technologies. So in the call, I mentioned that we started to deploy multi-busbar solar module, that kind of [Inaudible]. So we are shifting from the five busbar to the multibusbar. Canadian Solar has always been on the leading front of the module technology.

We're one of the first to move from three busbar to four busbar and then from four to four busbar. And now I think we will lead the shift or the upgrade from five busbar to multi-busbar. And we have been producing more and more bifacial solar modules. So I guess that's how we see the supply demand situation on the value chain, how we plan our capacity works.

Colin Rusch -- Oppenheimer & Company -- Analyst

Thanks so much. And then just I want to follow up on the comment around the bifacial because we're continuing to see kind of significant interest in that. What's your view on how quickly that technology gets adopted and how much market share it's going to take over the next couple of years?

Shawn Qu -- Chairman and Chief Executive Officer

We have -- we believe we have mastered the process for bifacials. So we are producing both multicrystalline and monocrystalline bifacial modules based on the P-type PERC technology. We have been producing those products -- well, we have started to produce those products massively. And in Q2, we'll produce over 100 megawatt of bifacials.

I don't know how other module companies are doing it. But for us, with Canadian Solar, we have mastered the bifacial technologies. We believe in it. And we have projects to deploy our bifacials in a massive way.

Operator

Thank you. Our next question comes from the line of Philip Shen from Roth Capital Partners. Please ask your questions.

Philip Shen -- Roth Capital Partners -- Analyst

First one is on ASPs. I think in your release, you talked about how your Q1 ASP increased. Can you talk about how that happened, which geography? Or what was the key driver of that? And then how do you expect the ASPs to trend into Q2 as well?

Shawn Qu -- Chairman and Chief Executive Officer

Yes, Philip, the branding and channel diversification really played a role here, really helped. So we secured many of our Q1 orders back in Q4. And then in Q1, although the market slowed down, but our customers, they see the value, I guess. So they stayed with us.

They sticked to the price. And I guess their investor and their bank also wanted them to stick with Canadian Solar. So we end up at almost the same ASP, slightly up. But I will say almost the same, slightly up from Q4 level.

However, moving from Q2, the ASP will go down. We don't guide the future ASP. But just the general trend is that Q2, the ASP of the module will go down. But fortunately, the material price from polysilicon to wafer, the material price also went down.

So our margin percentage is OK in Q2.

Philip Shen -- Roth Capital Partners -- Analyst

Great. Shifting to the balance sheet a bit and specifically interest expense, you gave us some detail on your debt levels. That said, want to ask the question about what you expect interest to be going forward. Do you expect it, for example, to be lower than Q1? And if you can give us what the Q2 interest expense might be, that would be great.

Shawn Qu -- Chairman and Chief Executive Officer

I think you are talking about interest expense, right?

Philip Shen -- Roth Capital Partners -- Analyst

Yes.

Shawn Qu -- Chairman and Chief Executive Officer

So I would expect the interest expense will go down because the debt level go down. We paid down a lot of debt. We paid down significant debt when we sold our solar project. So I would expect the interest payment -- interest expenses to go down.

Philip Shen -- Roth Capital Partners -- Analyst

OK, great, just wanted to confirm. And then in terms of Japan, can you update us on that region for you, especially the projects that you plan to drop down into your J-REIT? So how many megawatts could you drop down in '18 and '19? What's the expectation? And also perhaps, what might be the timing of the 2018 drop-downs be?

Shawn Qu -- Chairman and Chief Executive Officer

So from our press release, you see the update of our COD plan, 2018 and 2019 COD plan. I will say our drop-down plan is in step with the COD plan, right? If once we COD, we will either drop down or we sell, right? If it's a small project, let's say, 1 megawatt project, 1 megawatt, 2 megawatt project, you can assume that we will prefer to drop down into the J-REIT. Now if we COD a big project, 13, 15 megawatt big projects, then we have more options. We can drop down.

We can also sell to an investor in a single transaction. Actually, in Q1 and Q3, you will probably see some announcements of a couple of large projects in Japan which we will either sell in a single transaction or drop down to the J-REIT.

Philip Shen -- Roth Capital Partners -- Analyst

Great. You said Q1 and Q3, I think. Did you mean Q2 or Q3? And when do you expect...

Shawn Qu -- Chairman and Chief Executive Officer

Right, Q2 and Q3. You're right.

Philip Shen -- Roth Capital Partners -- Analyst

OK, good. So some drop-downs or some sales in the coming quarters. OK, one last one. Well, in terms of China, what do you expect the Chinese market to do year on year? Do you expect it to be flat? Last year, it was 53 gigawatts.

Or with the discussion out there about DG being a potential risk factor to the downside, could China be smaller -- could installations in 2018 be down year on year relative to '17? What's your overall view on the Chinese market now?

Shawn Qu -- Chairman and Chief Executive Officer

Well, Philip, I believe you will be in China for the SNEC show in 10 days, right? So you will find out. At this moment, my guess is as good as yours. I think the most probable scenario will be flat, almost flat. But if, let's say, if the government make a major announcement, especially on DG, and if they make an immediate cut, then the volume can also shrink.

The current draft of the EEA policy, if the DG project already registered with the provincial agency, will continue to be allowed. And that was why they drafted the policy. But the draft policy to the final policy -- well, sometimes it change, right? Let's say, if they believe this particular line, then, well, then I don't know what we will do with the DG project they already registered. But today, I read on the industry -- or some of the industry websites that there are China gigawatt of DG projects registered.

That seems to be the new number. I guess, that's why people rushed to register after the draft policy was announced, right? But India also have this piece of information. Let's see how they react to the situation.

Operator

Thank you. [Operator insctructions]. Our next question comes from the line of Brian Lee from Goldman Sachs. Please ask your questions.

Brian Lee -- Goldman Sachs -- Analyst

Hey, guys. Thank you for taking the questions. Maybe just quick housekeeping one. Are you making any changes to the full-year revenue or module shipment targets? I didn't see any updates in the release.

Shawn Qu -- Chairman and Chief Executive Officer

Well, no.

Brian Lee -- Goldman Sachs -- Analyst

OK. And then in your prepared remarks, Shawn, you mentioned some demand softness on modules. If you were to exclude shipments to your own projects, how much were your volumes down versus Q1 of last year? And I guess, similarly, if you exclude expected shipments for projects in Q2, what rough rate of decline are you forecasting versus last year? I guess I'm just trying to get a sense of where organic volume demand levels are trending through the first half of the year.

Shawn Qu -- Chairman and Chief Executive Officer

Well, our Q1, Q1 this year, our total shipment is 1.37 gigawatts as you see from our press release. We also gave you the reference of the Q1 -- Q1 2017, as I referenced, I believe that roughly is 1.33 gigawatts. So you can say that, "Hey, this Q1 is almost the same level of last Q1." I think that reflects the seasonality, so it's not a big surprise. Usually, Q1 is a slow season.

It's just another slow season like before. However, it also means, at least in our case, there was no growth, no significant year-over-year growth this year over next year. And in the past, you always expect growth, right? But think, the fact that there was no growth, the reason of probably the -- all those trade decisions, like the Section 201 from U.S., and all those trade challenges in India. Did I answer your question?

Brian Lee -- Goldman Sachs -- Analyst

Yes. And I guess maybe just to clarify a little bit, what number of megawatts did you ship to your own projects in Q1 of last year and also for the just reported Q1 of this year? I'm just trying to normalize for those to get to a sense of what your third-party module shipments were year on year. And then same question for 2Q, just sort of what's the third-party shipment level forecast implying on a year-on-year basis?

Shawn Qu -- Chairman and Chief Executive Officer

I don't have that number on my fingertips. But I think most of the Q1 shipments is third party. So you can assume maybe 90% or 95% or even more of our Q1 shipments went to third party. Because Q1 is linear.

So if other people help their utility to grow in the construction will also help.

Brian Lee -- Goldman Sachs -- Analyst

OK, fair enough. I'll take it offline. Second question is just around the margin outlook for 2Q. Can you -- it's quite a big increase from what you just reported here.

Can you speak to some of the mix assumptions or geographic exposure assumptions that you're embedding in there for the rise in gross margins for 2Q?

Shawn Qu -- Chairman and Chief Executive Officer

The manufacturing business is more or less stable. In Q1, our manufacturing gross margin is in highteens. And in Q2, we also see it in a high-teen level. So that shows that we have a good ability to maintain the manufacturing cost and price structure.

If the price goes down, we manage it to reduce the cost as well. And the difference from Q1 to Q2 all come from the solar projects we sold in the quarter. In Q1, the transactions we completed include some U.S. projects, some of the U.S.

projects which we CODed in 2015. At that time, the business model of the industry was yieldco. So we also accumulated some projects. But now there's no yieldco, Yieldco is not a factor anymore in the U.S.

Therefore, we're selling those projects. And those sales has low margins as we've mentioned. We also mentioned that in the press release. Now in Q2, we are also starting some projects in Q2.

Those were new projects. So projects we newly developed, developed last year and we sold in Q2, those projects have healthy margin. Therefore, the blended margin average there, about 20%.

Brian Lee -- Goldman Sachs -- Analyst

OK. No, that's very helpful. Maybe last question on that same topic. I missed it, Huifeng, I think, said in the next month or next several months.

But is the Shenzhen Energy sale of their Recurrent assets, the second slug of Recurrent assets, is that baked into your 2Q forecast? Or is that later in the year?

Shawn Qu -- Chairman and Chief Executive Officer

Well, I will just say that we haven't released the name of our future sales. So you can guess, but we don't make that -- we haven't released that information yet. And then I'll leave the rest to Huifeng

Huifeng Chang -- Chief Financial Officer

Brian, you understand -- the final outcome, before it happens, it's never 100% sure. However, we remain optimistic in the result. Like every other cases, it will take several months to get approval because [Inaudble] is short of staff. But the fact that we have been giving a lot of efforts, the fact that we already got approval for KEPCO, so we can get -- we are making progress every week.

We're getting close. We don't know if eventually the final results, when to come out. We believe and we are hopeful for a yes. But even approval or disapproval, once that happens, we'll report to the investors.

Thank you.

Brian Lee -- Goldman Sachs -- Analyst

OK. Yes, I just -- you've made to several comments in past calls and on this call that the margins on those projects are expected to be on the lower end. So I'm just wondering if the 20% to 22% gross margin guidance for 2Q captures the potential for those projects to be sold or if those margin targets would not actually reflect that. That was all I was trying to get at.

Huifeng Chang -- Chief Financial Officer

Brian, for that, I need to clarify that guidance for Q2 does not assume the close of the deal in the other three solar projects in Q2. However, it may happen. But just to be conservative, we have not included that in Q2 guidance.

Operator

Thank you. [Operator instructions] Our next question comes from the line of John Segrich from Luminus.

John Segrich -- Luminus Management-Analyst

Hi, guys. Just a couple more housekeeping questions. Could you give us the amount of capex in the quarter? And then secondly, Huifeng, can you just give us a sense of how much project revenue is included in 2Q? And then finally, maybe just can you walk which projects booked as revenue and which were booked as other income in 1Q, just so we can try to piece them apart?

Shawn Qu -- Chairman and Chief Executive Officer

The first one, Huifeng, do you have the number?

Huifeng Chang -- Chief Financial Officer

Yes, I'll handle them.

Shawn Qu -- Chairman and Chief Executive Officer

Huifeng is digging out the number for you.

Huifeng Chang -- Chief Financial Officer

John, let's -- I'll [Inaudible] and report the numbers. The cash -- the capex for the quarter was around U.S. $80 million for Q1, U.S. $8-0 million.

And then for Q1, most of -- for Q1, for the most of the projects we sold in Q1, we got around [Inaudible] projects because we are [Inaudible] other income in Q1. If you need any [Inaudible] numbers, I can provide after the call. For Q2, I think majority, almost 100% of the projects we currently include in our forecast was [Inaudible]. And almost all of them are the cells which we'll build at the projects, including those in Brazil and some of them in other areas.

But for that big one, the three U.S. -- the- the three big solar assets in California, we have not included that yet.

John Segrich -- Luminus Management-Analyst

Got it, OK. So of the $690 million to $730 million, about how much of the project, just ballpark?

Huifeng Chang -- Chief Financial Officer

OK. Around $150 million was the project sales in Q2 -- Q2 forecast

John Segrich -- Luminus Management-Analyst

Sorry, 1-1-5, is that what you said?

Huifeng Chang -- Chief Financial Officer

$150 million -- $140 million, 1-4-0

Operator

Thank you. Our next question comes from the line of Brad Meikle from Ampac Research. Please ask your question.

Brad Meikle -- Ampac Energy Research -- Analyst

Hi, good morning, and thanks for taking the questions. I think about a year ago, you had target of $0.25 a watt by 2020 as your outlook. Is that still your targeted cost per watt? And can you just discuss sort of the non-silicon cost per watt reduction drivers and how you see that over the next three years?

Shawn Qu -- Chairman and Chief Executive Officer

Yes, still see $0.25 as our cost target per solar module for 2020.

Brad Meikle -- Ampac Energy Research -- Analyst

And what are the main technology paths you see for driving non-silicon cost per watt down over the next medium term?

Shawn Qu -- Chairman and Chief Executive Officer

First of all, we think that the polysilicon process technology have improved a lot. And so that drove the cost down. And many of the new polysilicon facility -- many polysilicon factories are built in low-electricity regions. As you know, electricity is a big part of the cost for polysilicon.

So we think that polysilicon, we will see some healthy polysilicon price reductions with the leading polysilicon factories can still make money, either with a significant price reduction. So that's number one. And then on the manufacturing side, the cost efficiency improved. The solar cell and solar module efficiency improved.

The cost also got reduced. And some technology directly reduced the cost. For example, we mentioned the multi-busbar technology, the solar module technology in the call. That technology helped us to reduce -- not only improved efficiency but also reduced the silver paste usage.

And silver is the biggest consumables in the solar cell process.

Brad Meikle -- Ampac Energy Research -- Analyst

Yes, OK And I'm sorry if this was asked already. What's your outlook on ASPs for the rest of the year, on the module ASPs?

Shawn Qu -- Chairman and Chief Executive Officer

I don't have outlook because I don't guide -- I don't want to guide my customers to negotiate with me.

Brad Meikle -- Ampac Energy Research -- Analyst

Right. Well, could you speak to your level of visibility on the year, how much of your capacity has been sold in terms of bookings for the rest of the year?

Shawn Qu -- Chairman and Chief Executive Officer

We have sold -- well, at this moment, we have sold the majority of our Q2 capacity. That's why we are -- that's how we gave guidance. For Q3 and Q4, we also sold a significant percentage of the capacity. I don't have the exact percentage on my fingertips.

But our guidance -- our annual guidance, we have good confidence.

Operator

Thank you. Our last question comes from the line of Carter Driscoll from B. Riley FBR. Please ask your question.

Carter Driscoll -- B. Riley FBR -- Analyst

So in terms of 2Q gross margin guidance, is it -- I guess I'm struggling to get to that figure. So is it reasonable to assume the first thing is just you're no longer going to have the sales -- the 309 that obviously pulled down from the Recurrent sales in the quarter, maybe a geographic shift with the lower contribution from some of our price-sensitive markets, like the U.S.A. and India, maybe a little bit more penetration in some of the newer markets? I mean, directionally, my thinking, those are the big components on a Q-to-Q basis that are leading to the improved gross margin.

Shawn Qu -- Chairman and Chief Executive Officer

Right. Well, first of all, still an answer to the previous question that we included about $140 million into the Q2 guidance. So that gives you a feeling of the level of projects also we have in Q2. And we've also mentioned that we didn't assume the sales of another three solar projects in U.S.

in Q2. If it indeed happens in Q2, then, well, everybody happy. We would like to know once it's complete. But to be on the safe side, we didn't include that in the assumption.

But if it indeed happens, then you will see the revenue jump and the ASP drop, just like in Q1, right? And so that's the directions for the energy business, for the solar project business. On the solar module side, the shipment into U.S. was low. And the new shipments into U.S.

is low after the Section 201 announcement. U.S. was a high-margin market last year. So yes, you're right.

That high-margin market goes into very small volume. We are still selling some inventory. We also have some inventories in the U.S. So we do have some sales.

We have the modules to support our customers. But the volume is low. And in Q2, there will be significant volume into China. And the other market takes some products.

So you can say that the volume shipped, the main volume shipped is from U.S. to China.

Carter Driscoll -- B. Riley FBR -- Analyst

Got it, that's helpful. Thank you. Are you seeing any upper pricing on -- upward pressure on project financing at least from the debt component? Just with the gradual raise in rates, do you expect anything material in the back half of the year, if that's maybe moving to 4x this year? Do you expect any at least in the U.S.?

Shawn Qu -- Chairman and Chief Executive Officer

We don't. For our -- for the project, we budget to build this year. We don't see the pressure on financing. Not really.

Carter Driscoll -- B. Riley FBR -- Analyst

And then on the newer markets, you did mention earlier, Shawn, Australia and Argentina and Korea. Which of those -- I mean, if I remember correctly, you were one of the first to aggressively go after Brazil, non-Brazilian. And of those 3, could any of those kind of mimic, maybe not quite the same scale as Brazil, but surprise to the upside in terms of where it could grow incrementally outside of your current targeted areas?

Shawn Qu -- Chairman and Chief Executive Officer

I think Australia has lots of potential. And we also have significant pipeline in Australia. I believe we made an announcement of a pipeline acquisition back in Q1. If you dig out that press release, you'll see the size of our pipeline in Australia.

Argentina, I'm not sure. On one hand, that country also has lots of sunshine. However, with the current currency crisis in Argentina, maybe it will not grow as quickly as Brazil. But again, I'm just speculating.

We are working on our first project there in Argentina. And let's see how Argentina government can handle this current, this couple of issues..

Carter Driscoll -- B. Riley FBR -- Analyst

If I remember correctly, you were pushing 100% capacity utilization in your Chinese facilities but not in non-China. Is there any -- has that changed materially? Are you allocating or building more outside of China at all on a sequential basis or plan to this year? Or could you give us a rough figure of what utilization was for your non-Chinese plants in the quarter?

Shawn Qu -- Chairman and Chief Executive Officer

Yes, in Q1 -- first of all, Q1, both China and non-China have some capacity underutilization. In China, it was more due to holiday, due to the Chinese New Year holiday. And also in China, it was because there was a trade policy change. Now moving to Q2, since improving, as you see that our volume also improved.

But we still have some underutilization outside China, in some of the factories outside China.

Carter Driscoll -- B. Riley FBR -- Analyst

OK. But not enough that it's materially changed your capacity expansion plans?

Shawn Qu -- Chairman and Chief Executive Officer

Well, it is all included. If the capacity is underutilized, so then the per unit depreciation will be higher. So all that impact is included in the Q2 margin guidance. So I'm pleased that although you're going to always see some facility underutilization, we still maintained a stabilized, slightly up gross margin.

That shows that we have successfully stabilized the ASP and we also reduced our cost. Now moving forward, we are only adding capacities in the place where the capacity can be used. That's for sure. And also we're only adding capacities with new -- with advanced technologies.

For example, for the module capacities, we'll only add the multi-busbar. And we believe those technology -- those capacity will be fully utilized. Otherwise -- I mean, in reality, we don't have enough of those multi-busbar solar module capacity. And then on the solar cell side, our new solar cell factory will be fully capable, fully equipped to use this PIV technology, which is black silicon plus PERC, and also fully equipped to produce the bifacial cells.

So yes, there might be capacity underutilizations. But if you only invest into good and new technology, hopefully your customer will -- our customers will take our product.

Carter Driscoll -- B. Riley FBR -- Analyst

Yes. No, I mean, that's the right thing to be doing. Has there been any thought to either building solar module capacity in the U.S. after 201?

Shawn Qu -- Chairman and Chief Executive Officer

We have been doing feasibility studies for several countries but no decision on U.S. at this moment

Operator

Thank you. I would now like to hand the conference back to the management for closing remarks. Over to you, sir.

Shawn Qu -- Chairman and Chief Executive Officer

All right. Thank you for your continued support. And if you have any further follow-up questions after today's call, please contact us. And have a nice day.

Operator

[Operator instructions]

Duration: 51 minutes

Call Participants:

Mary Ma -- Investor Relations

Shawn Qu -- Chairman and Chief Executive Officer

Huifeng Chang -- Chief Financial Officer

Colin Rusch -- Oppenheimer & Company -- Analyst

Philip Shen -- Roth Capital Partners -- Analyst

Brian Lee -- Goldman Sachs -- Analyst

John Segrich -- Luminus Management-Analyst

Brad Meikle -- Ampac Energy Research -- Analyst

Carter Driscoll -- B. Riley FBR -- Analyst

More CSIQ analysis

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

10 stocks we like better than Canadian SolarWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Canadian Solar wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of May 8, 2018